Study population and patient characteristics
liver malignancies, colorectal liver metastases
ADVERSE EVENTS, MALIGNANCIES, LIVER METASTASES, COLORECTAL CARCINOMA
Out of 413 patients scheduled for interstitial brachytherapy of liver malignancies (e.g., colorectal liver metastases), 36 patients met the inclusion criteria and volunteered in participation. Two patients withdraw participation in each group shortly after informed consent leading to 16 patients entering the regular study schedule in the treatment and control arm, respectively. Required data acquisition were achieved in 16 patients per group.All patients had up to three liver metastases of various malignancies (colorectal carcinoma Intention to treat: patient characteristics of the study population including treatment characteristics and adverse events (AE)*